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Abstract
Inflammatory bowel diseases have a high frequency in Europe. They are chronic disorders that
evolve with relapses and remissions. Clinical features include the signs of underlying inflammatory
bowel disease and also signs of extraintestinal manifestations. Cutaneous disorders are the most
common extraintestinal manifestations associated with inflammatory bowel diseases, which can be
dependent on or independent of gastrointestinal disease activity. The main cutaneous disorders are
erythema nodosum and pyodermagangrenosum. The pathogenic mechanisms are not fully understood
but it seems that related mechanisms are involved in the development of inflammatory bowel diseases
and extraintestinal manifestations. Treatment should be aimed at both the cutaneous manifestations and
the bowel inflammation.
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Introduction
Inflammatory bowel diseases (IBD) comprise Crohn’s disease (CD) and ulcerative colitis (UC).
In Europe, there are 2.2 million people suffering of IBD (1). The etiology remains unknown, but studies
have shown that environmental, immunologic and genetic factors are involved. CD and UC share similar
features regarding their clinical appearance and pathogenesis, however there are some differences. CD
may affect any segment of the digestive tract, while UC involves only the colon and rectum (2). IBD are
associated with numerous extraintestinal manifestations, the cutaneous disorders being the ones most
frequently seen (3). Cutaneous lesions are diverse and sometimes difficult to diagnose.
Cutaneous manifestations can be divided into three categories: specific manifestations, reactive
manifestations and manifestations frequently associated with IBD. The specific lesions exhibit the same
histopathological characteristics (non-caseous granulomas) as those observed in intestinal mucosa, as
they share similar pathogenic mechanisms. Non-specific lesions, also called reactive lesions, are based
on immune processes targeting similar antigens located in the gut and skin (3, 4).

Discussion
1. Specific cutaneous manifestations in IBD
Oral aphtae
Usually, oral lesions are simultaneous with IBD flares. Aphtous ulcers are commonly seen in
patients with IBD. Clinically they resemble classical aphtae, but histopathologically granulomatous
lesions that are similar to those identified in the gutmay be seen. They occur as sharply defined round
ulcers, with erythematous margins. The treatment of the underlying bowel disease leads to the remission
of the lesions. Topical anesthetics may be applied (5, 6).
Mucosal nodularity
Oral mucosa is fissured and swollen with a cobblestone-like appearance, the lesions being
typically located on the posterior oral mucosa. In the course of the disease painful papules may be
90
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observed which merge and form plaques resulting in speech and eating impairment. There is no evidence
of any correlation between the occurrence of these lesions and IBD activity. Topical corticosteroids are
useful (6).
Perianal lesions
Perianal lesions are more frequent in patients with CD than UC, especially in those with colonic
or rectal lesions. The lesions may vary from fistulas to abscesses and strictures or deep ulcerations which
may damage the perianal sphincter. The possible complications are sepsis and fecal incontinence.
Treatment includes antibiotics, azathioprine and biological agents (infliximab) and sometimes surgical
procedures are needed (7, 8).
Metastatic CD
Metastatic CD is the equivalent of Crohn’s disease involving the skin. Metastatic CD is a rare
granulomatous disease, being more commonly reported in young women (9). The lesions usually
consist of papules, plaques or nodules with or without ulceration, located mainly on the limbs and skin
folds. The genital area may also be involved, physical examination revealing erythematous, ulcerated
and fissured lesions. The diagnosis should rule out other granulomatous diseases such as tuberculosis or
sarcoidosis. Metronidazole or corticosteroids may be used. Severe cases may require the administration
of immunosuppressive agents or surgery (3, 4).

2. Non-specific (reactive) cutaneous manifestations
Erythema nodosum
Erythema nodosum (EN) is the most frequent cutaneous manifestation associated with IBD,
being more commonly observed in patients with UC as compared to patients with CD. EN is a septal
panniculitis, with a female predominance. In most cases its etiology remains unknown, but it may occur
in the context of systemic diseases such as malignancy, infections (tuberculosis), sarcoidosis, etc. The
lesions appear as red painful ill-defined nodules of various dimensions (1-10mm), more accessible to
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palpation than direct observation, located generally on pretibial area. Healing is achieved in a few
months without scarring. Recurrences are frequent (10, 11).
IBD exacerbation leads to the occurrence or worsening of EN lesions. In patients with Crohn’s
disease, EN usually appears in those with colonic involvement (12). Studies have shown that
polynuclear cells identified in EN lesions release various cellular mediators which play a role in the
activation of other cells and in self-activation. The main identified cytokines were IL 8 and IL 6 which
were also highlighted in pyodermagangrenosum (PG). Often PG and EN occur simultaneously in a
patient, which suggests that there are similar elements involved in their pathogenesis (13). The
administration of non-steroidal anti-inflammatory drugs represents the treatment of choice, but in
patients with IBD it should be avoided. Systemic steroids and intralesional triamcinolone are effective.
Other therapies include hydroxychloroquine, colchicine, cyclosporine, thalidomide and infliximab (14).
Pyodermagangrenosum
Pyodermagangrenosum is a rare neutrophilic dermatosis in the general population, but it has an
increased incidence among persons with IBD. PG is also associated with rheumatological diseases,
myeloproliferative disorders and neoplasms. An underlying disease is identified in 50-70% of patients
with PG, the association with UC being reported most often. The onset may be before or after the
occurrence of IBD signs, but more frequently after it. The course of PG may or may not be influenced
by the activity of underlying intestinal disease. Thus cases of PG after proctocolectomy were reported
(15, 16). A recent study has shown that on average the onset of PG took place 15 years after the
diagnosis of IBD was made and the patients had been diagnosed with IBD at an older age (17).
The mechanism of development of PG is unclear. It seems that it is based on an autoimmune
process, auto-antibodies being directed against components of intestinal mucosa and skin. In the
pathogenesis, various cellular mediators such as interleukins (IL8, IL16, IL17) and TNF alpha are
involved (12). In addition, abnormal responses of lymphocytes and neutrophils impairment were
suggested (16). According to some authors, patients with severe IBD are more likely to develop PG and
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the course of PG is correlated with IBD flares (8). PG is more common in women, but there are studies
emphasizing a male predominance. It was typically reported after a trauma on legs. PG is a debilitating
condition, which starts with papules, vesicles or pustules resulting in painful ulcerative lesions with
irregular violaceous borders (18).
There are four types of PG: ulcerative, pustular, bullous and vegetative. The ulcerative form is
the most common. Histopathologically there is evidence of a neutrophilic infiltrate in the dermis, as the
disease progresses an infiltrate consisting of mononuclear cells surrounding areas of necrosis develops
(19). The treatment is difficult. Systemic or topical corticosteroids or immunosuppressive agents should
be used along with the treatment of the underlying intestinal disease. Therapy of IBD with biological
agents proved to be effective for PG lesions (18).
Sweet’s syndrome
The association between Sweet’s syndrome (SS), a rare neutrophilic dermatosis and IBD is
uncommon; most cases have been reported in women. According to the medical literature, about 40
cases have been described. The majority of patients had colonic involvement and based on this
observation scientists raised the hypothesis of the involvement of intestinal bacterial antigens in the
disease development (20). The onset of the lesions overlaps IBD flares, but SS may be diagnosed before
the diagnosis of IBD or it may occur after proctocolectomy (21). Some authors consider that SS is a type
III hypersensitivity reaction or a dysfunction of neutrophils or T cells is involved. The histopathological
findings display aneutrophilic infiltrate in the superior dermis. Leukocytoclasia without vasculitis may
also be observed. Clinically the lesions vary from papules to nodules, being painful and erythematous,
located typically on the cephalic extremity, upper limbs and trunk (22). It is associated with fever and
neutrophilia. Patients may present oral stomatitis and oral ulcerations. Corticosteroids are the optimal
treatment; methotrexate, cyclosporine, dapsone have been also reported to be successful in the therapy.
Relapses are common (23).
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Pyostomatitis/ pyodermatitis vegetans
Pyostomatitisvegetans (PV) is a chronic benign disorder, the equivalent of pyodermatitis
vegetans, affecting the mucous membranes, mainly oral mucosa. The diagnosis of PV requires
investigations for an inflammatory bowel disease. On oral mucosa the lesions occur as pustules and
vesicles which develop into ulceration. Genital, nasal or conjunctival mucosa may be involved (24).
Pyodermatitis vegetans is characterized by the appearance of vegetating well-defined plaques (25). In
most cases, eosinophilia is present. Histopathologically, abscesses mostly consisting of neutrophils are
observed. Several hypotheses on the pathogenesis of the disease have been postulated. The involvement
of a microbial agent was presumed but none has been revealed (26). Corticosteroids represent the firstline treatment. They may be administered in combination with antibiotics and immunosuppressive
agents. The oral lesions can be alleviated with local corticosteroids and antiseptic solutions (14).
Leukocitoclastic vasculitis
Leukocitoclastic vasculitis is a rare disorder encountered in patients with UC, which parallels the
evolution of the intestinal disease. The association between the two disorders may be due to the immune
complexes formation in both bowels and vessels. Histopathological features exhibit inflammation in the
postcapillary venules and nuclear detritus. Sulfasalazine and colchicine may be used as therapeutic
options (27).
3. Cutaneous manifestations frequently associated with IBD
Epiermolysis bullosa acquitsita
Epiermolysis bullosa acquitsita (EBA) is an acquired bullous chronic disease, the main trigger
being trauma. It was reported that 30% of patients diagnosed with EBA suffer of IBD. The two diseases
evolve independently of each other (14). Usually lesions consist of blisters that occur after an injury of
the skin. Subsequently, they heal with scarring and milia formation (28). In patients with EBA, Ig G and
Ig Aautoantibodies directed against type VII collagen, a component of the basement membrane zone, are
identified. Histopathological examination display ssubepidermal blisters and inflammatory infiltrate in
94
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the dermis (29). Direct immunofluorescence reveals immunoglobulin deposits within epidermal-dermal
junction. Colchicine is the treatment of choice. Cyclosporine is also effective. High doses of
corticosteroids, methotrexate, azathioprine or biological agents (rituximab) proved to be useful in the
therapy (28).
Linear Ig A bullous dermatosis
Linear Ig A bullous dermatosis is an acquired autoimmune disorder affecting both children and
adults. It manifests clinically as urticarial lesions, with peripheral vesicles or as a bullous eruption with
tense blisters that evolve into ulcerations. In most cases the mucous membranes are involved (30).
Histopathological findings consist of subepidermal blisters and neutrophilic infiltrate in basement
membrane. Direct immunofluorescence shows linear IgA deposits and sometimes IgG and complement
deposits along the basement membrane zone (31). The course of the disease is not correlated with the
bowel disease activity, symptoms persisting in some cases even after colectomy. Linear IgA dermatosis
is more common in patients with UC (32). It is thought that, patients with UC have an increased
production of monomeric IgA in colonic mucosa; there is a cross-reaction between lamina lucida and
lamina densa antigens. Dapsone is the treatment of choice (30).
Psoriasis
Studies have shown a higher incidence of psoriasis in patients with IBD in comparison with the
general population. It seems that there are similar mechanisms regarding the pathogenesis of IBD and
psoriasis, identifying increased levels of TNF alpha in both psoriasis and Crohn’s disease lesions (33). In
addition, in both diseases Th 17 lymphocytes stimulated by IL 23 play an important role. Involvement of
related pathogenic mechanisms is also suggested by the efficiency of infliximab and adalimumab in the
therapy of the two diseases (34). Regarding the genetic determinism, it seems that chromosomal loci
6p22, 16q, 1p31 and 5q33 are involved in both diseases (35).
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Conclusions
Cutaneous manifestations may occur before or after the diagnosis of IBD was made. It is
important to know the extraintestinal manifestations associated with IBD because their recognition may
lead to an early diagnosis of IBD. On the other hand, patients with IBD should be investigated in order
to diagnose these cutaneous manifestations. Cutaneous manifestations may or may not be influenced by
the disease activity. Sometimes, they are difficult to diagnose, a high degree of suspicion being
necessary. Therefore, the association between IBD and multiple cutaneous manifestations must always
be kept in mind.
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